What do systematic reviews say?

Laparoscopic gastrectomy vs open gastrectomy

• Laparoscopic versus open gastrectomy for gastric cancer 2016 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 472 participants
  Very low

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).

• Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
  HR 0.92 [0.8, 1.05]
  10 studies · 3843 participants
  Low

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).

• Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
  HR 0.9 [0.78, 1.04]
  11 studies · 4014 participants
  Low

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

• Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 53 participants
  Very low

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall response rate Duration of compared with chemotherapy alone (low certainty).

• Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
  OR 1.24 [1, 1.55]
  11 studies · 3723 participants
  Low

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher adverse event (any) Duration of compared with chemotherapy alone (moderate certainty).

• Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
  OR 2.23 [1.27, 3.92]
  5 studies · 2290 participants
  Moderate

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher severe adverse event (grade ≥ 3 ) Duration of compared with chemotherapy alone (moderate certainty).

• Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
  OR 1.19 [1.03, 1.37]
  8 studies · 3800 participants
  Moderate

Antithrombin vs placebo

It is very uncertain whether antithrombin changes neonatal mortality (all‐cause, < 28 days of age) compared with placebo (very low certainty).

• Antithrombin for the prevention of intraventricular hemorrhage in very preterm infants 2016 · Cochrane Headline outcomes only
  RR 2 [0.62, 6.45]
  2 studies · 182 participants
  Very low

Heparin vs placebo/no treatment

Heparin showed no clear difference in severe IVH compared with placebo/no treatment (low certainty).

• Heparin for the prevention of intraventricular haemorrhage in preterm infants 2016 · Cochrane Headline outcomes only
  RR 1.01 [0.46, 2.23]
  2 studies · 155 participants
  Low

Heparin vs placebo/no treatment

Heparin showed no clear difference in neonatal mortality (all‐cause) compared with placebo/no treatment (low certainty).

• Heparin for the prevention of intraventricular haemorrhage in preterm infants 2016 · Cochrane Headline outcomes only
  RR 0.69 [0.28, 1.67]
  2 studies · 155 participants
  Low

Rutosides vs placebo

The review found no eligible studies for this question.

• Interventions for varicose veins and leg oedema in pregnancy 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

External pneumatic intermittent compression vs rest

The review found no eligible studies for this question.

• Interventions for varicose veins and leg oedema in pregnancy 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Percutaneous endoscopic gastrostomy vs nasogastric tube feeding

Percutaneous endoscopic gastrostomy may leads to lower treatment failure Feeding interruption, blocking or leakage of the… compared with nasogastric tube feeding (low certainty).

• Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances 2015 · Cochrane Headline outcomes only
  RR 0.18 [0.05, 0.59]
  8 studies · 408 participants
  Low

Percutaneous endoscopic gastrostomy vs nasogastric tube feeding

It is very uncertain whether percutaneous endoscopic gastrostomy changes mortality irrespective of compared with nasogastric tube feeding (very low certainty).

• Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances 2015 · Cochrane Headline outcomes only
  RR 0.86 [0.58, 1.28]
  9 studies · 644 participants
  Very low

Percutaneous endoscopic gastrostomy vs nasogastric tube feeding

Percutaneous endoscopic gastrostomy showed no clear difference in pneumonia irrespective of compared with nasogastric tube feeding (low certainty).

• Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances 2015 · Cochrane Headline outcomes only
  RR 0.7 [0.46, 1.06]
  7 studies · 645 participants
  Low

Percutaneous endoscopic gastrostomy vs nasogastric tube feeding

Percutaneous endoscopic gastrostomy showed no clear difference in adverse events irrespective of compared with nasogastric tube feeding (moderate certainty).

• Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances 2015 · Cochrane Headline outcomes only
  RR 0.83 [0.51, 1.34]
  6 studies · 597 participants
  Moderate

Drain vs No drain

It is very uncertain whether drain changes 30‐day mortality Death during the compared with no drain (very low certainty).

• Abdominal drainage versus no drainage post‐gastrectomy for gastric cancer 2015 · Cochrane Headline outcomes only
  RR 1.73 [0.38, 7.84]
  4 studies · 438 participants
  Very low

Drain vs No drain

• Abdominal drainage versus no drainage post‐gastrectomy for gastric cancer 2015 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 4 participants
  Low

Drain vs No drain

It is very uncertain whether drain changes re‐operations Re‐operations during the compared with no drain (very low certainty).

• Abdominal drainage versus no drainage post‐gastrectomy for gastric cancer 2015 · Cochrane Headline outcomes only
  RR 2.49 [0.71, 8.74]
  2 studies · 230 participants
  Very low

Drain vs No drain

• Abdominal drainage versus no drainage post‐gastrectomy for gastric cancer 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 378 participants
  Low